On Jun. 14 2022, Pfizer reported data from the Phase 2/3 EPIC-SR (Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients) study evaluating the use of PAXLOVID (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) in patients who were at standard risk for developing severe COVID-19.